Skip to content

US · PMCB · BIOTECHNOLOGY

PharmaCyte Biotech, Inc. (PMCB) intrinsic value and stock valuation

$3.98as of 2026-11-21 · Mkt cap 4.01M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

PharmaCyte Biotech, Inc. DCF and intrinsic value

InvestorsCraft values PMCB with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from PMCB’s statements →

PharmaCyte Biotech, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Las Vegas, NV 89169 pharmacyte.com

How the business is doing

Fiscal 2012–2026, USD

Revenue
$0.00
20122026
Net income
-$-19.42M
20122026
Free cash flow
-$-5.15M
20122026
Total equity
$35M+39.3% 5y CAGRd
20122026

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2026, USD
20262025202420232022
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-5.3M-$-4.38M-$-6.52M-$-6.46M-$-4.39M
Net income-$-19.42M$30.7M$330K-$-4.32M-$-4.24M
EPSd-$-2.32M$4.18M$34.4K-$-833.98K-$-818.53K
Operating cash flow-$-5.15M-$-2.98M-$-2.15M-$-3.79M-$-4.12M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-5.15M-$-2.98M-$-2.15M-$-3.79M-$-4.12M
Total assets$46.8M$55.2M$59.9M$73.3M$90.6M
Total debt$0.00$0.00$0.00$0.00$0.00
Net debt-$-18.6M-$-15.17M-$-50.18M-$-68.04M-$-85.4M
Total equity$35M$51.9M$39.5M$72.7M$89.9M
Cash and short-term investments$37.1M$15.5M$50.2M$68M$85.4M
Income statement
20262025202420232022
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$391.3B$440K$410K$470K$690K
Selling, general and administrative expenses$4.91T$3.94M$6.11M$5.99M$3.7M
Other expenses-$-5.3T$0.00-$0.00-$0.00-$0.00
Operating expenses$5.3M$4.38M$6.52M$6.46M$4.39M
Cost and expenses$5.3M$4.38M$6.52M$6.46M$4.39M
Interest income$730K$1.42M$3.4M$1.94M$160K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$0.00$4.38M$6.52M$6.46M$4.39M
Ebitda-$-6.85T$30.7M$6.85M-$-4.32M-$-4.24M
Operating income-$-5.3M-$-4.38M-$-6.52M-$-6.46M-$-4.39M
Total other income/expenses, net-$-14.12M$35M$6.85M$2.14M$150K
Income before tax-$-19.42M$30.7M$330K-$-4.32M-$-4.24M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-19.42M$30.7M$330K-$-4.32M-$-4.24M
Weighted average shares outstanding$8.38M$7.33M$9.58M$19.5M$15.5M
Weighted average diluted shares outstanding$8.38M$7.33M$9.58M$5.18M$5.18M
Balance sheet
20262025202420232022
Cash and short-term investments$37.1M$15.5M$50.2M$68M$85.4M
Net receivables$240K$3.7M$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$37.4M$22.4M$50.4M$68.2M$85.5M
Property, plant and equipment, net$0.00$0.00$0.00$0.00$0.00
Goodwill and intangible assets$0.00$1.55M$1.55M$3.55M$3.55M
Long-term investments$0.00$22.5M$0.00$1.57M$1.57M
Total non-current assets$9.33M$32.8M$9.46M$5.13M$5.13M
Total assets$46.8M$55.2M$59.9M$73.3M$90.6M
Accounts payable$270K$400K$390K$130K$210K
Short-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$830K$2.91M$7.42M$590K$700K
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$9.26M$360K$13M$0.00$0.00
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$11.8M$3.28M$20.4M$590K$700K
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-104.39M-$-84.97M-$-115.63M-$-115.96M-$-111.65M
Accumulated other comprehensive income (loss)-$-20K-$-20K-$-20K-$-20K-$-20K
Total equity$35M$51.9M$39.5M$72.7M$89.9M
Total investments$18.5M$22.8M$0.00$1.57M$1.57M
Total debt$0.00$0.00$0.00$0.00$0.00
Net debt-$-18.6M-$-15.17M-$-50.18M-$-68.04M-$-85.4M
Cash flow statement
20262025202420232022
Net income-$-19.42M$30.7M$330K-$-4.32M-$-4.24M
Depreciation and amortization$0.00$0.00$0.00$0.00$0.00
Stock-based compensation$1.13M$480K$670K$650K$80K
Change in working capital-$-1.92M$1.36M$300K-$-300K$10K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-130K$10K$260K-$-240K$30K
Net cash provided by operating activities-$-5.15M-$-2.98M-$-2.15M-$-3.79M-$-4.12M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$2M-$-7M-$-5M$0.00$0.00
Common stock issued$1.05M$0.00$33.7M$0.00$87.4M
Common stock repurchased-$-400K-$-25.03M-$-44.36M-$-13.56M$0.00
Dividends paid-$-250K$0.00$0.00$0.00$0.00
Net cash used for financing activities$6.58M-$-25.03M-$-10.71M-$-13.56M$87.3M
Net change in cash$3.43M-$-35.01M-$-17.86M-$-17.36M$83.2M
Cash at end of period$18.6M$15.2M$50.2M$68M$85.4M
Operating cash flow-$-5.15M-$-2.98M-$-2.15M-$-3.79M-$-4.12M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-5.15M-$-2.98M-$-2.15M-$-3.79M-$-4.12M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About PharmaCyte Biotech, Inc.

        PharmaCyte Biotech, Inc. is a biotechnology firm dedicated to the development and commercialization of advanced cellular therapies within the United States. Their primary therapeutic areas include various forms of cancer, diabetes, and malignant ascites. Central to their efforts is Cell-in-a-Box, their proprietary encapsulation technology which utilizes cellulose to enclose live cells. This innovative platform serves as the foundation for treatments aimed at diverse cancers, such as advanced and inoperable pancreatic cancer, as well as diabetes. The company's pipeline includes therapies for pancreatic and other solid cancerous tumors; a treatment for Type 1 and insulin-dependent Type 2 diabetes involving encapsulated, genetically modified insulin-producing cells; and cancer treatments derived from cannabis plant compounds. To further its research, PharmaCyte maintains collaborative agreements: one with the University of Technology, Sydney, for the creation of melligen cells to combat diabetes, and another with the University of Northern Colorado, focusing on methods for identifying, separating, and quantifying cannabis constituents. Originally established in 1996, the company operated under the name Nuvilex, Inc. before rebranding as PharmaCyte Biotech, Inc. in January 2015. Its corporate headquarters are located in Las Vegas, Nevada.

        CEO
        Joshua N. Silverman
        Employees
        2
        Beta
        0.68

        Explore

        Frequently asked questions

        What is the intrinsic value of PharmaCyte Biotech, Inc. (PMCB)?

        InvestorsCraft does not currently publish an intrinsic value for PMCB. How the IC value is calculated.

        Is PMCB undervalued?

        InvestorsCraft does not publish an undervaluation signal for PMCB at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.